Get the Stockscreener App
38.65
1.18%
-0.46
Bright Minds Biosciences Inc stock is traded at $38.65, with a volume of 51,471.
It is down -1.18% in the last 24 hours and up +18.30% over the past month.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$39.11
Open:
$38.39
24h Volume:
51,471
Relative Volume:
0.02
Market Cap:
$269.56M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-19.91
EPS:
-1.9408
Net Cash Flow:
$-3.85M
1W Performance:
-5.73%
1M Performance:
+18.30%
6M Performance:
+3,581%
1Y Performance:
+2,622%
1-Day Range:
$36.81
$39.10
1-Week Range:
$36.06
$43.40
52-Week Range:
$0.93
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
38.65 | 269.56M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% – Time to Sell? - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3%Time to Sell? - MarketBeat
Retail investors among Bright Minds Biosciences Inc.'s (CSE:DRUG) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Baird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform Recommendation - MSN
Bright Minds Buosciences Surges 5,900% Last Week. Attention Turning To Cybin ($CYBN) Rallying 23% On Upcoming... - Daily Scanner
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Strong-Buy" at Baird R W - MarketBeat
Bright Minds initiated at outperform by Baird, Longboard takeover cited - MSN
Bright Minds initiated at outperform by Baird, Longboard takeover cited (NASDAQ:DRUG) - Seeking Alpha
Baird assigns Outperform to Bright Minds stock, sees positive readthrough from recent M&A - Investing.com Nigeria
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Bright Minds to Present BMB-101 Epilepsy Drug Data at Major AES 2024 Conference | DRUG Stock News - StockTitan
Bright Minds Biosciences participates in a conference call with Truist - Nasdaq
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - The Manila Times
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - GlobeNewswire Inc.
RA Capital Management, L.P. Acquires New Stake in Bright Minds B - GuruFocus.com
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month - Yahoo Finance
A Billion-Dollar Private Placement Highlights Recent Insider Buying - 24/7 Wall St.
When (DRUG) Moves Investors should Listen - Stock Traders Daily
Cormorant Asset Management's Strategic Acquisition of Bright Min - GuruFocus.com
Bright Minds Biosciences Secures $35 Million Investment - Yahoo Finance
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement - The Manila Times
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga
🚀 Wall Street Radar: Stocks to Watch Next Week - substack.com
Top 4 Canadian Biotech Stocks of 2024 - Investing News Network
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential - Seeking Alpha
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.47% - MSN
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Short Interest Up 1,274.9% in October - MarketBeat
Steven Cohen's Strategic Acquisition of Bright Minds Biosciences Inc Shares - GuruFocus.com
Rivian Automotive Inc (NASDAQ: RIVN): Blank Check On Growth? - Stocks Register
Logos Global Management LP Acquires New Stake in Bright Minds Bi - GuruFocus.com
Bright Minds rebounds after $35M private placement - MSN
Soaring $1-handle stocks leaping into IBKR’s most-active list may point to market froth - MSN
Cormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences Shares - Yahoo Finance
Bright Minds Stock Skyrockets After $35M Private Placement Amid Volatility - SpeaksLY
$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds
Bright Minds Biosciences (DRUG) Partners with Firefly Neuroscience, Resulting in Stock Surge - TipRanks
Bright Minds and Firefly Neuroscience Renew Collaboration - TipRanks
What's Going On With Bright Minds Biosciences Stock? - Benzinga
Such Is The Power Of Bright Minds Biosciences Inc (NASDAQ: DRUG) - Stocks Register
Cigna and Humana re-engage in merger talks - Yahoo! Voices
Gen Z demands improved payment options for insurance in UK - Yahoo! Voices
2 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - Yahoo! Voices
Bright Minds, Firefly Neuroscience Shares Rise on Collaboration for Clinical Trial Analysis - MarketWatch
Bright Minds, Firefly Neuroscience to collaborate after BREAKTHROUGH study - TipRanks
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data - The Manila Times
Netflix's Third-Quarter Results Exceeded Expectations. But Is the Stock a Buy? - Yahoo! Voices
In data: Value, luxury, sportswear set to drive Turkish apparel market - Yahoo! Voices
Fuzzy’s Taco Shop announces new leadership roles - Yahoo! Voices
SB Energy’s Orion Solar Belt begins commercial operations in US - Yahoo! Voices
KIMS signs MOU with Wipro GE Healthcare for medical technologies - Yahoo! Voices
Nordic and BeeKeeperAI partner to accelerate AI clinical support systems - Yahoo! Voices
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bright Minds Biosciences Inc Stock (DRUG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 10% Owner |
Oct 15 '24 |
Buy |
5.53 |
372,591 |
2,061,574 |
825,000 |
| Cormorant Asset Management, LP | 10% Owner |
Oct 16 '24 |
Buy |
23.46 |
50,000 |
1,172,813 |
875,000 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):